不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>Beckman Coulter将收购西门子临床微生物诊断业务

Beckman Coulter将收购西门子临床微生物诊断业务

互联网2014年7月18日 8:58 点击:4486


     西门子


2014年7月16日,贝克曼库尔特发布声明说已经同意收购西门子医疗诊断的临床微生物学业务,交易价格未透露。

不用本金就能赚钱的方法  XIMENZILINCHUANGWEISHENGWUXUEYEWUZHUANMENCONGSHIWEISHENGWUJIANDINGHEYAOMINSHIYAN(ID/AST),QIYEWUYUNZUOJICHUSHIQUANQIUYIJINGANZHUANGDECHAOGUO6000TAIYIQI,GAIYEWUSHIXIMENZIZHENDUANBUMENDEYIBUFEN,QUNIANWANCHENGLE53.32YIMEIYUAN(€39.42YI)DESHOURU。

  XIMENZIWEISHENGWUCHANPINXIANBAOKUOMicroScanYIQI、MicroScanBAN/XIAOHAOPIN,YIJISHUJUGUANLIJIEJUEFANGAN。MicroScanZHIZAITIGONGGAOJINGDUHEYOUYUEDEXINXINGNAIYAOXINGJIANCE。

  “LINCHUANGWEISHENGWUXUEYEWUJIANGSHIYIGEHENHAODEBUCHONG,WEILAIBEIKEMANKUERTEDEZHENDUANYEWUJIANGYONGYOUGENGQIANGDADESHENGYUHESHICHANGDIWEI,”BEIKEMANKUERTEZHENDUANYEWUDONGSHIZHANGArnd KaldowskiZAIYIFENSHENGMINGZHONGSHUO。“ZAIWOMENXIANYOUDECHANPINHEFUWUZHONGZENGJIAID/ASTWEIWOMENCHUANGZAOLEYIGEJIHUI,RANGWOMENWEISHIYANSHIKEHUTIGONGGENGDUODECHANPINHEFUWU,YIJIGAISHANDUIBINGRENDEHULI。”

不用本金就能赚钱的方法   KaldowskiBUCHONGSHUO,CICISHOUGOUJIANGKUODABEIKEMANKUERTETIGONGCHAYIHUACHANPINZUHEDENENGLI,TISHENGKEHUDELINCHUANGGONGNENG,BAOCHIGONGSIDECHIXUZENGZHANG。

   西门子与贝克曼库尔特的这一交易预计在2015年第一季度完成。

Beckman To Buy Siemens Healthcare Diagnostics' Clinical Microbiology Business

不用本金就能赚钱的方法 Beckman Coulter said today it agreed to acquire the clinical microbiology business of Siemens Healthcare Diagnostics for an undisclosed price.

不用本金就能赚钱的方法Siemens’ clinical microbiology business specializes in microbial identification and antibiotic sensitivity testing (ID/AST). The business operates with an installed base of over 6,000 instruments globally, and is part of Siemens’ diagnostics division, which finished last year with $5.332 billion (€3.942 billion) in revenue.

不用本金就能赚钱的方法Today’s announcement by Beckman Coulter—an indirect, wholly owned subsidiary of Danaher—ends months of speculation over the future of Siemens’ clinical microbiology business. In March, BioMerieux CEO Jean-Luc Belingard told Reuters his company would look at acquiring the business from Siemens, which the wire service said had been offering through bankers “around $500 million” for its clinical microbiology operations, citing unnamed sources.

不用本金就能赚钱的方法Siemens’ microbiology product line includes the MicroScan® Instruments and MicroScan panels/consumables, along with data management solutions. The MicroScan systems are designed to deliver high accuracy and superior detection of emerging resistance.

“The clinical microbiology business will be an excellent complement to Beckman Coulter's Diagnostics business with a strong reputation and market position,” Beckman Coulter Diagnostics President Arnd Kaldowski said in a statement. “Adding its ID/AST solutions to our existing products and services will create an opportunity to enhance our offerings to laboratory customers and improve patient care.”

Kaldowski added that the acquisition will expand Beckman Coulter’s product portfolio with differentiated analytical systems that elevate the company’s clinical capabilities for customers, while driving continued growth.

不用本金就能赚钱的方法Siemens’ deal with Beckman Coulter is expected to close in the first quarter of 2015, subject to regulatory approvals and other customary closing conditions.

Earlier this month, Bloomberg reported that Siemens was looking to refocus on its energy and industrial businesses, citing unnamed sources as saying the German conglomerate was also looking to sell off its hospital database and IT business.

Adding credence to that talk was Siemens restructuring its operations in May, in part by giving greater operational independence to its healthcare businesses. CEO Joe Kaeser at the time insisted that the action was not intended to signal a sell-off but to increase their ability to address a changing market.

However, Morningstar analyst Debbie Wang speculated to the Boston Business Journal that Siemens may still wish to grow in diagnostics, saying the company was one of two most likely suitors for Alere. The comment followed a shakeup of Alere’s management that led an outspoken shareholder to say publicly that the point-of-care diagnostics developer had received unsolicited offers from potential strategic acquirers in the past year.
 

 

(来源: 互联网 )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图